ScreenerHero

NRXSNeuraxis Inc. Common Stock

AMEX · US · Healthcare · Biotechnology · neuraxis.com
6.150USD-3.60%Mkt Cap: 77.23M $P/E: —

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap77.23M $
Enterprise Value69.19M $
Revenue (TTM)5.32M $
Gross Profit3.01M $
Net Income (TTM)-7.80M $
Revenue/Share0.4880 USD
Last Price6.150 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees24
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-22.78
PEG—
EV/EBITDA-9.09
EV/Revenue13.02
P/S14.53
P/B11.39
EPS (TTM)-0.76
EPS (Forward)-0.27
52W Range
2.21055% of range9.330
52W High9.330 USD
52W Low2.210 USD
Profitability
Gross Margin84.23%
Oper. Margin-110.16%
EBITDA Margin-143.13%
Profit Margin-218.55%
ROE-229.47%
ROA-121.81%
Growth
Revenue Growth115.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-6.43M $
CapEx (TTM)131.15K $
FCF Margin-59.35%
FCF Yield-4.09%
Net Debt-8.04M $
Net Debt/EBITDA1.06
Balance Sheet
Debt/Equity0.12
Current Ratio3.04
Quick Ratio2.83
Book Value/Sh0.5400 USD
Cash/Share0.6630 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)11.00 USD
Upside (mean)+78.9%
Target Range9.000 USD – 13.00 USD
$9.000+78.9% to mean$13.00
# Analysts2
Ownership
Shares Out.12.56M
Float8.45M
Insiders20.63%
Institutions28.44%
Short Interest
Short Ratio5.2d
Short % Float4.29%
Short % Out.3.35%
Shares Short418.13K
Short (prev mo.)358.65K
Technical
SMA 506.783 (-9.3%)
SMA 2005.775 (+6.5%)
Beta1.48
S&P 52W Chg19.18%
Avg Vol (30d)88.82K
Avg Vol (10d)114.18K
Technical Indicators
RSI (14)39.6
MACD-0.1657
MACD Signal-0.1316
MACD Hist.-0.0341
BB Upper7.205 USD
BB Middle6.547 USD
BB Lower5.889 USD
BB Width20.11%
ATR (14)0.4010 USD
Vol Ratio (20d)0.98x